Age-Related Macular Degeneration Market: Overview, Growth, Trends, and Key Players (2034)

Age-Related Macular Degeneration Market Overview

The age-related macular degeneration market has emerged as a critical segment in the global healthcare landscape, primarily due to the rising geriatric population worldwide. Age-related macular degeneration (AMD) is a progressive eye condition that affects the macula, the central part of the retina, leading to central vision loss. As life expectancy increases globally, so does the incidence of AMD, making it a significant public health concern and a major driver for innovation in ophthalmology.

Get a free sample report: https://bit.ly/4laPJNS

In 2024, the age-related macular degeneration market was valued at USD 10.46 Billion. This growth is driven by the increasing prevalence of AMD, greater awareness among patients, and ongoing advancements in diagnostics and therapeutics. The market is projected to grow at a CAGR of 9.70% from 2025 to 2034, reaching an estimated value of USD 26.40 Billion by 2034.

Market Size and Share Analysis

The size and share of the age-related macular degeneration market reflect robust development across both developed and emerging economies. North America leads the global market due to a combination of high disease prevalence, a well-established healthcare infrastructure, and strong R&D investments. The U.S. holds the largest share in the region, supported by major players like Regeneron and Roche having a firm presence.

Europe follows closely, with countries like Germany, France, and the UK being major contributors. Asia-Pacific, on the other hand, is emerging as the fastest-growing region, with rapidly aging populations in Japan, China, and South Korea fueling demand for AMD treatments.

2024 Market Value: USD 10.46 Billion

2034 Forecast Value: USD 26.40 Billion

CAGR (2025-2034): 9.70%

Wet AMD, or neovascular AMD, holds the largest market share due to the availability of effective anti-VEGF therapies such as Eylea, Lucentis, and Beovu. Dry AMD, though more prevalent, has limited treatment options, representing a key area of unmet need and future opportunity.

Market Dynamics and Emerging Trends

Drivers Fueling Market Growth

Growing geriatric population: With the number of people aged 65 and above increasing globally, age-related diseases like AMD are becoming more prevalent.

Advancements in drug delivery and imaging: Innovations in OCT (Optical Coherence Tomography), AI-powered screening, and sustained-release therapies are improving diagnostics and treatment outcomes.

Increasing awareness and early diagnosis: Public health campaigns and educational programs are leading to early detection, improving prognosis and increasing demand for treatment.

Emerging Market Trends

Development of gene therapies and regenerative medicine: Companies are exploring gene-editing technologies and stem cell therapies to target the root causes of AMD.

Shift towards long-acting treatments: There's a growing demand for therapies that reduce treatment burden, such as extended-release implants and bispecific antibodies.

AI integration in diagnosis: Artificial intelligence is being integrated with retinal imaging for faster and more accurate AMD detection and monitoring.

Teleophthalmology and remote care: Especially post-COVID-19, remote screening and teleconsultations are gaining traction, increasing access to diagnosis in rural areas.

Read full report with table of content: https://bit.ly/4mrRAyT

Growth Potential of the Age-Related Macular Degeneration Market

The age-related macular degeneration market is expected to witness exponential growth in the coming decade. A key reason is the expanding base of AMD patients, especially in developing regions where access to treatment is improving. Additionally, the transition from symptom management to disease modification is opening new avenues of growth.

Investments in research and partnerships between biotech startups and pharma giants are expected to accelerate the development of breakthrough treatments. Government initiatives to support vision health, especially among aging populations, are further propelling the market forward.

Notable Growth Contributors:

Introduction of next-gen anti-VEGF drugs with improved efficacy and dosing frequency.

Expansion in emerging markets, especially in Asia-Pacific and Latin America.

Pipeline candidates in late-stage trials, particularly for dry AMD which currently lacks approved therapies.

Market Opportunities and Challenges
Major Market Opportunities

Untapped potential in dry AMD treatment: With limited approved therapies, the dry AMD segment offers lucrative growth prospects.

Emerging biotech collaborations: Startups focusing on novel mechanisms of action are being funded or acquired by larger players to diversify their AMD portfolio.

Expansion of AI and telemedicine: Widening access to early AMD screening in underdiagnosed populations through digital tools offers significant market expansion potential.

Key Challenges

High treatment costs: Anti-VEGF injections can be expensive and require frequent administration, posing affordability and compliance issues.

Regulatory hurdles: Gene therapies and novel biologics often face longer regulatory review timelines, slowing product launches.

Patient adherence: Many AMD treatments require multiple injections over extended periods, which can lead to drop-offs in patient compliance.

Recent Developments in the Age-Related Macular Degeneration Market

The age-related macular degeneration market has witnessed a flurry of developments in recent years:

Regeneron Pharmaceuticals has expanded Eylea's indications and is working on a high-dose version to reduce injection frequency.

Roche's Vabysmo (Faricimab) received FDA approval for AMD and diabetic macular edema (DME), introducing a bispecific antibody to the market.

Novartis continues to advance Beovu and explore novel AMD therapies through acquisitions and in-house R&D.

Apellis Pharmaceuticals gained FDA approval for Pegcetacoplan (Syfovre), the first treatment specifically approved for geographic atrophy (a severe form of dry AMD).

Comprehensive Competitor Analysis

The competitive landscape of the age-related macular degeneration market is moderately consolidated, with several global players dominating the anti-VEGF space. However, increasing R&D in dry AMD and gene therapies is encouraging the entry of new players.

Key Players in the Age-Related Macular Degeneration Market
Bayer AG

Bayer is a co-developer of Eylea along with Regeneron and continues to play a significant role in the AMD market, especially in Europe and Asia. The company is also investing in cell therapy and ophthalmic research.

F. Hoffmann-La Roche Ltd.

Roche has established a strong presence through Lucentis and now Vabysmo. Its pipeline includes next-gen treatments aiming to increase dosing intervals and improve patient outcomes.

Novartis AG

Novartis leads in ophthalmology with Beovu and extensive research into long-acting and sustained-release therapeutics. The company is also exploring biosimilars for AMD treatment.

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN)

Regeneron is a leader in the AMD market, with Eylea generating multi-billion-dollar revenues annually. The company is pushing the boundaries with high-dose Eylea and new molecules targeting alternative AMD pathways.

Others

Additional notable participants include Apellis Pharmaceuticals (Syfovre), Kodiak Sciences (KSI-301), and Iveric Bio (Zimura), which are all pursuing novel approaches for both wet and dry AMD.

Frequently Asked Questions (FAQ)

What is age-related macular degeneration (AMD)?
AMD is a degenerative eye condition that affects the macula, leading to loss of central vision, particularly in older adults.

What are the two main types of AMD?

Dry AMD (atrophic): More common but less severe; progresses slowly.

Wet AMD (neovascular): Less common but more severe; involves blood vessel leakage and rapid vision loss.

What is driving the growth of the AMD market?
The rising geriatric population, growing awareness, technological advancements, and pipeline developments are primary growth drivers.

Which region dominates the AMD market?
North America currently dominates the market, followed by Europe. However, the Asia-Pacific region is witnessing the fastest growth due to aging demographics and improved healthcare access.

Who are the leading companies in the AMD market?
Major players include Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., and Apellis Pharmaceuticals.

What are the major treatment options for AMD?
Anti-VEGF therapies like Eylea, Lucentis, and Beovu are commonly used. Newer treatments like Vabysmo and Syfovre are expanding the therapeutic arsenal.

Is there a cure for AMD?
Currently, there is no cure, but treatments can slow progression and manage symptoms. Research is ongoing for disease-modifying therapies and potential cures through gene therapy.

Find More Report:

Dementia Drugs Market: https://bit.ly/3IXwPwz

Liver Fibrosis Market: https://bit.ly/3TOmC87

Panic Disorder Market: https://bit.ly/4o1JtLg

Biologics Market: https://bit.ly/3GOIayw

Medical Wellness Market: https://bit.ly/4mac6UT

Media Contact:

Company Name: Claight Corporation
Contact Person: Deepanshu Choudhary, Digital Marketing
Email: sales@expertmarketresearch.com
Toll Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others. Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

This release was published on openPR.